# A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Source: https://onco.cc/trials/nct07284849/  
OnCo record `nct07284849` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing INCA33890 in colorectal cancer, now recruiting.

## Summary

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer is a phase 3 interventional study registered as NCT07284849, led by Incyte, and recruiting on the registry. Official title: A Randomised, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer. Planned enrolment is 700 participants (estimated). The study started in 2026-03-05 and primary completion is expected in 2028-12-29. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07284849
- Phase: 3
- Setting: A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
- Sponsor: Incyte
- Enrolled: 700

## Sources

- ClinicalTrials.gov NCT07284849: https://clinicaltrials.gov/study/NCT07284849

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [INCA33890](https://onco.cc/drugs/inca33890/)
- companies: [Incyte](https://onco.cc/companies/incyte/)

---
JSON: https://onco.cc/api/v1/entities/nct07284849.json